

BIOMARIN PHARMACEUTICAL INC
 Form 4
 March 04, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)
 Director 10% Owner
 Officer (give title below) Other (specify below)
 Chief Executive Officer

(Last) (First) (Middle)
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2015

(Street)
SAN RAFAEL, CA 94901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	Price	Shares held by
Common Stock	03/02/2015 ⁽¹⁾	03/02/2015	M		3,000	A \$ 12.99	46,195 I Bienaime Family Trust ⁽²⁾
Common Stock	03/02/2015 ⁽¹⁾	03/02/2015	S		3,000	D \$ 107.9643 ⁽³⁾	43,195 I Bienaime Family Trust ⁽²⁾

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock	03/02/2015	03/02/2015	S	5,000	D	\$ 108.4389 (4)	220,157	D	
Common Stock	03/03/2015	03/03/2015	S	5,000	D	\$ 107.4193 (5)	215,157	D	
Common Stock	03/04/2015	03/04/2015	M	500	A	\$ 9.86	43,695	I	Shares held by Bienaime Family Trust
Common Stock	03/04/2015	03/04/2015	S	916	D	\$ 107.7079 (6)	42,279	I	Shares held by Bienaime Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy Common Stock)	\$ 12.99	03/02/2015	03/02/2015	M	3,000	11/11/2006 ⁽⁷⁾	05/10/2016	Common Stock	3,000
Stock Option (right to buy)	\$ 12.99 (5)					11/11/2006 ⁽⁷⁾	05/10/2016	Common Stock	10,000

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Trade made pursuant to a 10b5-1 plan executed November 6, 2014

(2) The reporting person and his spouse act as trustees for the Bienaime Family Trust

The price in column 4 is an average weighted price. The price actually received ranged from \$106.96 to \$108.66. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

The price in column 4 is an average weighted price. The price actually received ranged from \$107.29 to \$108.82. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

The price in column 4 is an average weighted price. The price actually received ranged from \$106.33 to \$108.49. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

The price in column 4 is an average weighted price. The price actually received ranged from \$109.68 to \$109.725. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

(7) Original option grant vests 6/48ths on November 11, 2006, and 1/48th on the 11th of every month thereafter.

(8) The reporting person's spouse is the trustee of each child's trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.